Akari Therapeutics (AKTX) vs Neuphoria Therapeutics (NEUP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Akari Therapeutics (AKTX) has outperformed Neuphoria Therapeutics (NEUP) over the past year, losing 80.1% versus a loss of 81.8%. Akari Therapeutics is the larger company by market cap ($18.6 million vs $18.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKTX | NEUP |
|---|---|---|
| Share price | $8.13 | $3.35 |
| Market cap | $18.58M | $18.13M |
| 1-day change | -5.74% | -2.05% |
| YTD return | -29.67% | -13.66% |
| 1-year return | -80.07% | -81.76% |
| 5-year return | -99.38% | — |
| EPS (TTM) | $0.00 | $-3.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $40.00 | $19.21 |
| 52-week low | $3.02 | $3.19 |
| Distance from 52-week high | -79.67% | -82.56% |
| Analyst consensus | none | none |
| Avg. price target upside | +213.65% | — |
| Average volume | 61.08K | 161.66K |
| Shares outstanding | 2.29M | 5.41M |
| Employees | 5 | 1 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Akari Therapeutics
AKTX stock →Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing.
Healthcare · Biotechnology · 5 employees
About Neuphoria Therapeutics
NEUP stock →Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder.
Healthcare · Biotechnology · 1 employees
AKTX vs NEUP FAQ
Which is bigger, Akari Therapeutics or Neuphoria Therapeutics?
Akari Therapeutics (AKTX) is larger, with a market capitalization of $18.58M compared with $18.13M for Neuphoria Therapeutics (NEUP).
Which stock has performed better over the past year, AKTX or NEUP?
AKTX returned -80.07% over the past 12 months, compared with -81.76% for NEUP (price return, excluding dividends). Past performance does not predict future results.
Are Akari Therapeutics and Neuphoria Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.